RhumbLine Advisers’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.39M | Buy |
244,338
+41,268
| +20% | +$781K | ﹤0.01% | 1539 |
|
|
2026
Q1 | $4.42M | Buy |
203,070
+12,962
| +7% | +$251K | ﹤0.01% | 1460 |
|
|
2025
Q4 | $4.09M | Buy |
190,108
+11,687
| +7% | +$246K | ﹤0.01% | 1500 |
|
|
2025
Q3 | $3.44M | Sell |
178,421
-88,893
| -33% | -$1.58M | ﹤0.01% | 1616 |
|
|
2025
Q2 | $4.57M | Buy |
267,314
+2,070
| +0.8% | +$88.3K | ﹤0.01% | 1458 |
|
|
2025
Q1 | $16.9M | Sell |
265,244
-2,689
| -1% | -$283K | 0.02% | 773 |
|
|
2024
Q4 | $32.6M | Sell |
267,933
-2,939
| -1% | -$360K | 0.03% | 479 |
|
|
2024
Q3 | $33.8M | Sell |
270,872
-69
| -0% | -$9.54K | 0.03% | 467 |
|
|
2024
Q2 | $42.8M | Buy |
270,941
+160,942
| +146% | +$20.7M | 0.04% | 368 |
|
|
2024
Q1 | $14.2M | Sell |
109,999
-8,473
| -7% | -$1.04M | 0.01% | 872 |
|
|
2023
Q4 | $11.4M | Sell |
118,472
-4,379
| -4% | -$420K | 0.01% | 985 |
|
|
2023
Q3 | $14.9M | Sell |
122,851
-1,011
| -0.8% | -$114K | 0.02% | 782 |
|
|
2023
Q2 | $14.2M | Buy |
123,862
+16,657
| +16% | +$2.15M | 0.02% | 830 |
|
|
2023
Q1 | $14.8M | Buy |
107,205
+6,377
| +6% | +$827K | 0.02% | 767 |
|
|
2022
Q4 | $13.1M | Buy |
100,828
+6,975
| +7% | +$808K | 0.02% | 801 |
|
|
2022
Q3 | $10.4M | Buy |
93,853
+5,634
| +6% | +$568K | 0.02% | 876 |
|
|
2022
Q2 | $6.61M | Buy |
88,219
+9,947
| +13% | +$732K | 0.01% | 1105 |
|
|
2022
Q1 | $6.12M | Sell |
78,272
-3,212
| -4% | -$246K | 0.01% | 1195 |
|
|
2021
Q4 | $7.34M | Buy |
81,484
+7,717
| +10% | +$660K | 0.01% | 1156 |
|
|
2021
Q3 | $6.82M | Sell |
73,767
-474
| -0.6% | -$36.5K | 0.01% | 1166 |
|
|
2021
Q2 | $5.77M | Sell |
74,241
-4,101
| -5% | -$311K | 0.01% | 1351 |
|
|
2021
Q1 | $5.84M | Sell |
78,342
-5,736
| -7% | -$529K | 0.01% | 1324 |
|
|
2020
Q4 | $14.3M | Sell |
84,078
-1,828
| -2% | -$271K | 0.02% | 714 |
|
|
2020
Q3 | $12.1M | Sell |
85,906
-3,019
| -3% | -$459K | 0.02% | 676 |
|
|
2020
Q2 | $14.3M | Buy |
88,925
+14,599
| +20% | +$1.99M | 0.02% | 598 |
|
|
2020
Q1 | $7.27M | Sell |
74,326
-352
| -0.5% | -$40.2K | 0.02% | 815 |
|
|
2019
Q4 | $9.64M | Buy |
74,678
+2,675
| +4% | +$270K | 0.02% | 855 |
|
|
2019
Q3 | $5.42M | Sell |
72,003
-644
| -0.9% | -$76.1K | 0.01% | 1143 |
|
|
2019
Q2 | $11M | Buy |
72,647
+5,482
| +8% | +$666K | 0.02% | 723 |
|
|
2019
Q1 | $8.01M | Sell |
67,165
-872
| -1% | -$112K | 0.02% | 891 |
|
|
2018
Q4 | $7.42M | Sell |
68,037
-230
| -0.3% | -$28.8K | 0.02% | 868 |
|
|
2018
Q3 | $11M | Buy |
68,267
+935
| +1% | +$128K | 0.02% | 642 |
|
|
2018
Q2 | $8.9M | Buy |
67,332
+6,473
| +11% | +$610K | 0.02% | 740 |
|
|
2018
Q1 | $4.51M | Sell |
60,859
-683
| -1% | -$45.5K | 0.01% | 1108 |
|
|
2017
Q4 | $3.42M | Sell |
61,542
-11,001
| -15% | -$583K | 0.01% | 1305 |
|
|
2017
Q3 | $3.29M | Buy |
72,543
+11,081
| +18% | +$443K | 0.01% | 1292 |
|
|
2017
Q2 | $2.07M | Buy |
61,462
+1,383
| +2% | +$45K | ﹤0.01% | 1560 |
|
|
2017
Q1 | $1.78M | Buy |
60,079
+2,082
| +4% | +$64.4K | ﹤0.01% | 1629 |
|
|
2016
Q4 | $1.59M | Buy |
57,997
+10,323
| +22% | +$415K | ﹤0.01% | 1588 |
|
|
2016
Q3 | $2.93M | Buy |
47,674
+955
| +2% | +$28.9K | 0.01% | 1169 |
|
|
2016
Q2 | $891K | Buy |
46,719
+721
| +2% | +$13.4K | ﹤0.01% | 1860 |
|
|
2016
Q1 | $898K | Sell |
45,998
-1,730
| -4% | -$30.2K | ﹤0.01% | 1862 |
|
|
2015
Q4 | $1.84M | Buy |
47,728
+6,615
| +16% | +$214K | 0.01% | 1413 |
|
|
2015
Q3 | $1.32M | Buy |
41,113
+1,601
| +4% | +$54.3K | ﹤0.01% | 1609 |
|
|
2015
Q2 | $1.2M | Sell |
39,512
-1,845
| -4% | -$37.7K | ﹤0.01% | 1749 |
|
|
2015
Q1 | $549K | Buy |
41,357
+7,475
| +22% | +$99.6K | ﹤0.01% | 2249 |
|
|
2014
Q4 | $490K | Sell |
33,882
-1,150
| -3% | -$19.5K | ﹤0.01% | 2288 |
|
|
2014
Q3 | $739K | Sell |
35,032
-3,665
| -9% | -$82.7K | ﹤0.01% | 1967 |
|
|
2014
Q2 | $1.15M | Buy |
38,697
+3,234
| +9% | +$102K | ﹤0.01% | 1727 |
|
|
2014
Q1 | $852K | Buy |
35,463
+2,240
| +7% | +$57.1K | ﹤0.01% | 1903 |
|
|
2013
Q4 | $677K | Buy |
33,223
+1,410
| +4% | +$41.9K | ﹤0.01% | 2063 |
|
|
2013
Q3 | $1.5M | Buy |
31,813
+3,653
| +13% | +$141K | ﹤0.01% | 1509 |
|
|
2013
Q2 | $1.07M | Buy |
+28,160
| New | +$1.01M | ﹤0.01% | 1712 |
|
Other funds holding SRPT
EAM
RhumbLine Advisers's SRPT Position: Q2 2026 in Review
RhumbLine Advisers increased its Sarepta Therapeutics (SRPT) stake by 20% in Q2 2026, buying an estimated $781K and bringing the position to 244,338 shares worth $4.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1539.
RhumbLine Advisers first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $42.8M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- RhumbLine Advisers held 244,338 shares of Sarepta Therapeutics worth $4.39M as of Q2 2026.
- RhumbLine Advisers bought 41,268 Sarepta Therapeutics shares in Q2 2026, an estimated $781K.
- Sarepta Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1539 holding.
- RhumbLine Advisers first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Sarepta Therapeutics position peaked at $42.8M in Q2 2024.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.